Efficacy and safety of tosufloxacin tosilate hydrate for the treatment of community-acquired pneumonia in children - Efficacy and safety of TFLX fine granules for the treatment of CAP in children

Start Date08 Oct 2010

Sponsor / Collaborator-

100 Clinical Results associated with Tosufloxacin Tosilate Hydrate

100 Translational Medicine associated with Tosufloxacin Tosilate Hydrate

100 Patents (Medical) associated with Tosufloxacin Tosilate Hydrate

299

Literatures (Medical) associated with Tosufloxacin Tosilate Hydrate

15 Oct 2024·Internal Medicine

Evidence of Tosufloxacin Deposition in the Kidneys of a Patient Presenting with Crystal Nephropathy

Article

Author: Kobayashi, Nao ; Mori, Noriko ; Mori, Kiyoshi ; Matsuo, Ken ; Mizuno, Hajime ; Nagai, Kojiro ; Todoroki, Kenichiro ; Tanaka, Satoshi ; Ito, Yuuki

Tosufloxacin tosilate is classified as a new quinolone antibacterial agent, which has been reported to cause crystal nephropathy. However, the origin of these crystal deposits has not yet been elucidated. We encountered a case of renal failure that progressed slowly owing to crystal-forming interstitial nephritis after long-term exposure to tosufloxacin. Mass spectrometry of the renal specimens revealed that tosufloxacin was deposited in the kidneys. The patient's renal function improved slowly with the withdrawal of tosufloxacin and steroid therapy. This is the first case to demonstrate the presence of crystal deposits consisting of tosufloxacin.

01 Aug 2024·Journal of Chromatography A

Preparation and optimization of dummy molecularly imprinted polymer-based solid-phase extraction system for selective enrichment of p-toluene sulfonate esters genotoxic impurities

Article

Author: Fu, Yao ; Liu, Huiyi ; Zhu, Zhiling ; Zuo, Limin ; Zhao, Xuejia ; Jiang, Yifei ; Shan, Guangzhi ; Lian, Xiaofang ; Qiu, Xiaodan ; Su, Wenling ; Jia, Qingying ; Yao, Jing ; Li, Yiran

Sulfonate esters, one class of genotoxic impurities (GTIs), have gained significant attention in recent years due to their potential to cause genetic mutations and cancer. In the current study, we employed the dummy template molecular imprinting technology with a dummy template molecule replacing the target molecule to establish a pretreatment method for samples containing p-toluene sulfonate esters. Through computer simulation and ultraviolet-visible spectroscopy analysis, the optimal functional monomer acrylamide and polymerization solvent chloroform were selected. Subsequently, a dummy template molecularly imprinted polymer (DMIP) was prepared by the precipitation polymerization method, and the polymer was characterized in morphology, particle size, and composition. The results of the adsorption and enrichment study demonstrated that the DMIP has high adsorption capability (Q = 7.88 mg/g) and favorable imprinting effects (IF = 1.37); Further, it could simultaneously adsorb three p-toluene sulfonate esters. The optimal adsorption conditions were obtained by conditional optimization of solid-phase extraction (SPE). A pH 7 solution was selected as the loading condition, the methanol/1 % phosphoric acid solution (20:80, v/v) was selected as the washing solution, and acetonitrile containing 10 % acetic acid in 6 mL was selected as the elution solvent. Finally, we determined methyl p-toluene sulfonate alkyl esters, ethyl p-toluene sulfonate alkyl esters, and isopropyl p-toluene sulfonate alkyl esters in tosufloxacin toluene sulfonate and capecitabine at the 10 ppm level (relative to 1 mg/mL active pharmaceutical ingredient (API) samples) by using DMIP-based SPE coupled with HPLC. This approach facilitated the selective enrichment of p-toluene sulfonate esters GTIs from complex API samples.

02 Jul 2024·Journal of Biomolecular Structure and Dynamics

Interaction of systemic drugs causing ocular toxicity with organic cation transporter: an artificial intelligence prediction

Article

Author: Sharma, Surbhi ; Malani, Manisha ; Hiremath, Manthan S ; Nirmal, Jayabalan ; Jhunjhunwala, Manisha ; Gayen, Shovanlal ; Hota, Chittaranjan

Chronic disease patients (cancer, arthritis, cardiovascular diseases) undergo long-term systemic drug treatment. Membrane transporters in ocular barriers could falsely recognize these drugs and allow their trafficking into the eye from systemic circulation. Hence, despite their pharmacological activity, these drugs accumulate and cause toxicity at the non-target site, such as the eye. Since around 40% of clinically used drugs are organic cation in nature, it is essential to understand the role of organic cation transporter (OCT1) in ocular barriers to facilitate the entry of systemic drugs into the eye. We applied machine learning techniques and computer simulation models (molecular dynamics and metadynamics) in the current study to predict the potential OCT1 substrates. Artificial intelligence models were developed using a training dataset of a known substrates and non-substrates of OCT1 and predicted the potential OCT1 substrates from various systemic drugs causing ocular toxicity. Computer simulation studies was performed by developing the OCT1 homology model. Molecular dynamic simulations equilibrated the docked protein-ligand complex. And metadynamics revealed the movement of substrates across the transporter with minimum free energy near the binding pocket. The machine learning model showed an accuracy of about 80% and predicted the potential substrates for OCT1 among systemic drugs causing ocular toxicity - not known earlier, such as cyclophosphamide, bupivacaine, bortezomib, sulphanilamide, tosufloxacin, topiramate, and many more. However, further invitro and invivo studies are required to confirm these predictions.Communicated by Ramaswamy H. Sarma.

100 Deals associated with Tosufloxacin Tosilate Hydrate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tosufloxacin Tosilate Hydrate	D07XA02 D07AA03 S02BA03 A07EA01 C05AA04 S03BA02 S01CB02 H02AB06 R01AD02 S01BA04	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Blepharitis	JP	Nitto Medic Co., Ltd.	23 Jan 2006
Corneal Ulcer	JP	Nitto Medic Co., Ltd.	23 Jan 2006
Dacryocystitis	JP	Nitto Medic Co., Ltd.	23 Jan 2006
Hordeolum	JP	Nitto Medic Co., Ltd.	23 Jan 2006
Keratitis	JP	Nitto Medic Co., Ltd.	23 Jan 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ERS2012	Not Applicable	MR gene	152	Macrolides	zbhdqirxlm(nhwdxwgswr) = The DNA copy numbers in the MR patients showed little decrease after macrolide administration, but rapid decrease after administration of minocycline or tosufloxacin yixqlbhdyu (fulbanwfdv )	-	01 Sep 2012
				Minocycline
63459 (ARVO2007)	Not Applicable	-	-	Moxifloxacin Ophthalmic Solution	tplcfwhcen(zjqldgziix) = sxqehrysey ymzyhborod (chstlaweaa )	Positive	01 May 2007
				Levofloxacin Ophthalmic Solution	tplcfwhcen(zjqldgziix) = tlubfxeqvf ymzyhborod (chstlaweaa )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tosufloxacin Tosilate Hydrate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation